Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Biofrontera, Inc. (the "Company") issued a press release announcing its preliminary unaudited revenues for the fourth quarter and year ended December 31, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Form 8-K") and is incorporated herein by reference.

The information contained in this Item 2.02 in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

The financial information set forth in this Form 8-K reflects the Company's current preliminary revenue estimates, is subject to the completion of its review process, and is subject to change. The Company's fourth quarter and full year ended December 31, 2022 results could differ materially from the preliminary estimates provided in this Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits.





99.1   Press release dated January 9, 2023
104  Cover Page Interactive Data File (the cover page XBRL tags are embedded

within the inline XBRL document)

© Edgar Online, source Glimpses